Data about FDA special protocol assessments might help public

02/9/2010 | Forbes

Though the FDA promised to be more transparent, legislation might be necessary to require the agency to disclose special protocol assessments with drugmakers, according to this blog. By making SPAs public, investors can become aware of the progress of drug trials, raising their confidence in their investments, the blog notes. Because the FDA treats SPAs as confidential, investors of Cell Therapeutics were unaware that the company's SPA was no longer valid, causing shares to drop 40% on Monday.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations